Why Nutex Health Inc. (NUTX) is Surging in 2025
We recently published a list of . In this article, we are going to take a look at where Nutex Health Inc. (NASDAQ:NUTX) stands against other healthcare stocks that are surging in 2025.
After lagging behind the broader market in 2024, many healthcare stocks are making a comeback this year. Healthcare spending has been continuously soaring and is projected to do so in the coming years due to demographic tailwinds. The industry now accounts for a fifth of the U.S. economy, and it's a good idea to have exposure to it.
Most executives now hold a favorable view of the industry's prospects, a notable increase from 52% just a year ago. Moreover, it's an industry that is more insulated from tariffs and macro risks.
Of course, the top gainers here are not defensive healthcare stocks, but it's still worth looking into the winners here if you are chasing potential multibaggers.
Even during bear markets, there are pockets of the market that perform exceptionally well. For example, I identified in another article.
For this article, I screened the best-performing healthcare stocks year-to-date.
I will also mention the number of hedge fund investors in these stocks. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points ().
A medical professional in scrubs providing care to a patient.
Number of Hedge Fund Holders In Q4 2024: 6
Nutex Health Inc. (NASDAQ:NUTX) is a physician-led healthcare services company operating micro-hospitals, population health management, and real estate segments across the United States.
The stock is up significantly so far in 2025 after the fourth-quarter and full-year 2024 earnings report, released in late March 2025, which showed total revenue nearly doubling to $479.9 million and net income swinging to $52.2 million from a $45.8 million loss the prior year. Adjusted EBITDA jumped over 1,000% to $123.7 million, and the hospital division saw visits rise by 17%.
A key driver behind this explosive growth was Nutex Health Inc. (NASDAQ:NUTX)'s strategic shift in mid-2024 to aggressively pursue arbitration under the No Surprises Act for out-of-network claims. This resulted in much higher reimbursement rates per visit and an over 80% success rate in claims.
The consensus price target of $80 implies 35.24% downside.
Nutex Health Inc. (NASDAQ:NUTX) stock is up 289.84% year-to-date.
Overall, NUTX ranks 4th on our list of healthcare stocks that are surging in 2025. While we acknowledge the potential of NUTX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than NUTX but that trades at less than 5 times its earnings, check out our report about this .
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
29 minutes ago
- Business Insider
RBC Capital Sticks to Its Hold Rating for CME Group (CME)
RBC Capital analyst Ashish Sabadra maintained a Hold rating on CME Group (CME – Research Report) on June 8 and set a price target of $269.00. The company's shares closed yesterday at $268.35. Confident Investing Starts Here: Sabadra covers the Industrials sector, focusing on stocks such as APi Group, Cintas, and Equifax. According to TipRanks, Sabadra has an average return of 6.1% and a 62.50% success rate on recommended stocks. In addition to RBC Capital, CME Group also received a Hold from KBW's Kyle Voigt in a report issued on June 4. However, on the same day, Oppenheimer reiterated a Buy rating on CME Group (NASDAQ: CME). CME market cap is currently $98.82B and has a P/E ratio of 27.57. Based on the recent corporate insider activity of 99 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CME in relation to earlier this year. Last month, Daniel Kaye, a Director at CME sold 500.00 shares for a total of $141,205.00.
Business Insider
29 minutes ago
- Business Insider
Nasdaq (NDAQ) Gets a Buy from RBC Capital
RBC Capital analyst Ashish Sabadra maintained a Buy rating on Nasdaq (NDAQ – Research Report) on June 8 and set a price target of $95.00. The company's shares closed yesterday at $85.65. Confident Investing Starts Here: According to TipRanks, Sabadra is a 5-star analyst with an average return of 6.1% and a 62.50% success rate. Sabadra covers the Industrials sector, focusing on stocks such as APi Group, Cintas, and Equifax. Currently, the analyst consensus on Nasdaq is a Moderate Buy with an average price target of $84.58. NDAQ market cap is currently $49.15B and has a P/E ratio of 38.82. Based on the recent corporate insider activity of 83 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NDAQ in relation to earlier this year. Last month, Pc Nelson Griggs, the Pres. Capital Access Platforms of NDAQ sold 8,000.00 shares for a total of $664,240.00.
Business Insider
an hour ago
- Business Insider
‘Nothing Lasts Forever,' Says Top Investor About Palantir Stock
Palantir (NASDAQ:PLTR) stock presents investors with quite a quandary. Confident Investing Starts Here: On the one hand, there is no denying that the company has delivered incredible growth over the past few years. Its revenues are skyrocketing, its margins are strong, and its list of customers continues to grow by leaps and bounds. Its share price has responded in kind, surging by over 466% over the past twelve months. And therein lies the rub, as PLTR is now trading at elevated multiples that are far and above the sector average. This leads to the question of whether all that company growth has led to enthusiasm that is a bit too optimistic. Top investor Riyado Sofian is decidedly on the fence, and is not sure which way the winds will blow. 'It's hard to decide whether to buy or sell — best to just hold it,' states the 5-star investor, who is in the top 3% of TipRanks' stock pros. Sofian outlines the bull case, describing a company that has introduced game-changing AI technology that sets the firm apart from its peers. Beyond the growing sales, profits, and customers, the investor also points out that revenues from Palantir's top 20 customers increased by 26% year-over-year, a strong indication of customer satisfaction. While the company continues to raise its guidance, it often succeeds in going well beyond these numbers, notes Sofian, and it has repeatedly 'destroyed its guidance' in previous quarters. In other words, more massive growth could be on the horizon for Palantir. 'All things considered, this is execution on an elite level — there's no denying it,' adds Sofian. And yet, judging by traditional metrics, the company is overvalued, the investor acknowledges, and its narrative as 'the most important AI company in the West' is what has powered its continuing ascent. For that reason, as long as the company's growth continues apace, PLTR should continue to rise as well. However, that is far from certain, and at a valuation of 100x its revenues, there is practically no room for error if the impressive rate starts to slow. To this point, Sofian reminds investors that nothing lasts forever. With neither a Buy nor a Sell looking particularly appealing, Sofian is splitting the difference and rating PLTR shares a Hold (i.e. Neutral). (To watch Sofian's track record, click here) That stance is echoed across Wall Street. Of the 18 analyst reviews on file, 11 say Hold, while just 3 recommend Buy and 4 suggest Sell, making PLTR a consensus Hold. The average 12-month price target sits at $101.06, implying a ~23% downside from current levels. (See PLTR stock forecast) To find good ideas for AI stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
